| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8964506 | Clinical Oncology | 2018 | 9 Pages |
Abstract
Utilisation of new targeted drugs and immune therapies for MM has increased considerably in routine practice 2007-2015. Consistent with the results of clinical trials, adoption was associated with substantial increases in survival of patients in the general population.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
T.P. Hanna, P. Nguyen, T. Baetz, C.M. Booth, E. Eisenhauer,